Gilead Sciences Inc. (GILD)
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T cell therapies underperforming. However, Trodelvy achieved good growth and now accounts for 5% of consolidated product sales. Sales guidance was raised by 2.4%, primarily due to Veklury, while non-GAAP EPS guidance was raised by 16% for several reasons which I will highlight in the article.
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago.
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance
Gilead Sciences Inc.'s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings.
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?
Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.
Ahead of Gilead (GILD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Earnings Preview: Gilead Sciences (GILD) Q3 Earnings Expected to Decline
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
Gilead Sciences (GILD) reachead $88.08 at the closing of the latest trading day, reflecting a -0.77% change compared to its last close.
